News

2016 Oct 17

Chemotherapy drives treatment resistance in bladder cancer

While chemotherapy kills the most common type of bladder cancer, urothelial cancer, it also shapes the genetic evolution of remaining urothelial cancer cell clones to become drug-resistant, according to Bishoy Faltas and colleagues. Read more

2016 Oct 10

Do I Have a Hidden Cancer?

A profile of Francis Barany, Ph.D., and some of his cancer detection tests. Read more

2016 Oct 10

Gene identified that drives aggressive prostate cancer

David Rickman, Ph.D., and colleagues have identified a gene that appears to regulate the change from prostate adenocarcinoma to neuroendocrine prostate cancer. Read more

2016 Oct 08

Alisertib may benefit certain patients with neuroendocrine prostate cancer

Alisertib monotherapy may be effective in certain patients with clinical or pathologically defined neuroendocrine prostate cancer, according to Himisha Beltran, M.D. Read more

2016 Oct 07

Chasing after ‘Compassionate Use’

Jeffrey Greenfield, M.D., Ph.D., speaks out about the need for wider - and speedier - use of the FDA compassionate use exception. Read more

2016 Oct 05

Pricey new treatment roils issues of how to treat prostate cancer

Drs. Jim Hu and Art Sedrakyan comment on the use of high-intensity focused ultrasound for prostate cancer treatment. Read more

2016 Sep 28

Weill Cornell, New York Genome Center Win NCI Grant to Support New TCGA Phase

A new collaboration will be formed to help further data analysis for the Cancer Genome Atlas project, thanks to a $490,000 grant from the National Cancer Institute. Read more

Mark Souweidane, M.D., and his eight-year-old DIPG patient, Brooke Blake

2016 Sep 28

Believe in Brooke: Finding peace with DIPG

A community has rallied around an 8-year-old with pediatric brain cancer, and the doctor who has saved her life so far with his experimental treatment. Read more

2016 Sep 28

Freezing technique is an effective alternative to lumpectomy for early stage breast cancer, study finds

A deep-freezing technique known as cryoablation is a viable alternative to traditional surgery in many early-stage breast cancers, according to Rache Simmons, M.D. Read more

2016 Sep 27

New drugs, immuno-oncology advances gastric cancer treatment paradigm

Immuno-oncology and the classification of subtypes of gastric cancer could greatly advance treatment efficacy and variation, according to Manish A. Shah, M.D. Read more

2016 Sep 26

Collaborative MDS research yields world-class results

The Weill Cornell Medicine Leukemia Program is part of collaborative research into myelodysplastic syndromes (MDS). Read more

2016 Sep 21

We Are Weill Cornell Medicine: Dr. Olivier Elemento

Olivier Elemento, Ph.D., is a featured faculty member in the #WeAreWCM campaign. Read more

2016 Sep 21

Moneyball could offer winning strategy for drug development

Researchers from the lab of Olivier Elemento, Ph.D., have developed a promising new AI tool that better predicts which drug candidates are likely to be too toxic. Read more

2016 Sep 20

Five questions for Harold Varmus

Harold Varmus, M.D., reflects on the state of medical research and the public's understanding of it, as well as politics. Read more

2016 Sep 20

Cancer Care: The Next Generation

Several Meyer Cancer Center faculty are featured in this half-hour television special on cancer. Read more

2016 Sep 19

The impact of Tecentriq to treat patients with advanced bladder cancer

The immunotherapy Tecentriq (atezolizumab) has been found to be non-toxic and has demonstrated a major survival advantage in patients with metastatic urothelial bladder cancer, according to David Nanus, M.D. Read more

2016 Sep 19

The cooperation that causes cancer

Ari Melnick, M.D., has uncovered the mechanisms by which B-cells can transform to cause cancer, and found that it requires a special cooperation between regulatory protein EZH2 and transcription protein BCL6. Read more

2016 Sep 19

The height of dedication

Matthew Bernstein, 16, is contributing to a cure for the cancer that claimed his brothers life. Read more

2016 Sep 16

Chemical tags on RNA silence X chromosome in females

The addition of a chemical tag on an RNA molecule is the critical switch that inactivates one X chromosome in every cell, ensuring healthy development in all female mammals, according to new research by Samie Jaffrey, Ph.D. Read more

2016 Sep 15

Identifying Genetic Changes in Advanced Prostate Cancer: What It Means for Patients

Himisha Beltran, M.D., discusses molecular-based tools used to examine genetic changes in prostate cancer. Read more

News

Chemotherapy drives treatment resistance in bladder cancer

Do I Have a Hidden Cancer?

Gene identified that drives aggressive prostate cancer

Alisertib may benefit certain patients with neuroendocrine prostate cancer

Chasing after ‘Compassionate Use’

Pricey new treatment roils issues of how to treat prostate cancer

Weill Cornell, New York Genome Center Win NCI Grant to Support New TCGA Phase

Believe in Brooke: Finding peace with DIPG

Freezing technique is an effective alternative to lumpectomy for early stage breast cancer, study finds

New drugs, immuno-oncology advances gastric cancer treatment paradigm

Collaborative MDS research yields world-class results

We Are Weill Cornell Medicine: Dr. Olivier Elemento

Moneyball could offer winning strategy for drug development

Five questions for Harold Varmus

Cancer Care: The Next Generation

The impact of Tecentriq to treat patients with advanced bladder cancer

The cooperation that causes cancer

The height of dedication

Chemical tags on RNA silence X chromosome in females

Identifying Genetic Changes in Advanced Prostate Cancer: What It Means for Patients

Follow us on X

2022 Annual Report

2021 Annual Report

2018 Annual Report

2017 Annual Report

2016 Annual Report

Newsletters